111,650 research outputs found
A Hashimoto-thyreoiditis és a papillaris pajzsmirigy-carcinoma kapcsolata
No full textKutatásunkban a Hashimoto-thyreoiditis (HT) és papillaris pajzsmirigy-carcinoma (PC) közti összefüggéseket vizsgáltuk. Bizonyos szerzők a PC multifocalitását HT-vel kísért esetekben gyakoribbnak találták, mint a HT nélküli PC-seknél, és ez alapján a HT-t a PC alapbetegségének tekintik, mások szerint viszont ez a különbség nem szignifikáns. Vizsgálatunkba a 2007 és 2012 között a DE KK Sebészeti Intézetben operált pajzsmirigy-carcinomás betegeket válogattuk be (43 HT-s és pajzsmirigy-carcinomás beteg, 5 férfi és 38 nő; 219 pajzsmirigy-carcinomás beteg HT nélkül, 48 férfi és 171 nő). Eredményeink szerint a HT-vel együtt jelentkező PC szignifikánsan gyakrabban multifocalis (16 MF (40,0%)/ 24 UF (60,0%)), mint a HT nélküli PC (45 MF (23,7%)/ 145 UF (76,3%), p = 0,034). A pN0 nyirokcsomó stádium szignifikánsan gyakoribb HT-vel kísért PC esetében (7 pN0 (63,6%)/ 4 pN1 (36,4%)), mint HT nélkül (7 pN0 (17,1%)/ 34 pN1 (82,9%), p = 0,002). A PC-ben és HT-ben is érintett betegek között szignifikánsan kisebb a férfiak aránya (4 férfi (10,0%)/ 36 nő (90,0%)), mint a csak PC-ben érintettek között (44 férfi (23,2%)/ 146 nő (76,8%), p = 0,046). Az életkor valamelyest alacsonyabb, a tumor és TNM-stádium pedig kevésbé előrehaladott HT-vel kísért PC esetében, mint HT nélkül, azonban ezek a különbségek nem szignifikánsak. A mindkét betegségben érintettek gyakoribb PC-multifocalitása arra utal, hogy a HT a PC alapbetegségének tekinthető, azonban a két betegség kapcsolatának természete egyelőre nem teljesen tisztázott.általános orvostudományinappalimagyaregységes, osztatla
Full QCD and QED at finite temperature and chemical potential
No full textBender I, Hashimoto T, Karsch F, Linke V, Nakamura A. Full QCD and QED at finite temperature and chemical potential. Nucl.Phys.Proc.Suppl. 1992;26:323-325
Hashimoto tiroiditinde anti-BIP düzeyleri
No full textHashimoto tiroiditli hastalarda immün modülatör ve antiapoptotik etkileri olan endoplazmik retikulum şaperonu BIP’e karşı oluşan antikor varlığını araştırmak.
Çalışmaya 20 ötiroid otoimmün tiroidit, 27 subklinik hipotiroidi, 15 hipotiroid hashimoto tiroiditi olmak üzere 62 otoimmün tiroiditli hasta ve 37 hastadan oluşan sağlıklı kontrol grubu alındı.
Hashimoto tiroiditli hastaların alt gruplarıyla kontrol grubu arasında ve hashimoto tiroiditi alt gruplarının kendi aralarında Anti-BIP düzeyleri açısından kıyaslandığında herhangi bir istatistiksel fark saptanmadı (p=0,889).
Tiroid hücrelerinde BIP aktivasyonu gösterilmesine rağmen bizim çalışmamızda hashimoto tiroiditli hasta alt gruplarında Anti-BIP düzeyi kontrol grubundan farklı bulunmamıştır. Bu durum hashimoto tiroiditinde apoptozis ve/veya T hücre cevabıyla BIP’e karşı oluşan antikorların ilişkisiz olduğu veya serumda tespit edilemeyecek düzeylerde olduğunu düşündürmektedir.
To asses the presence of antibodies to BIP/GRP78, which is a chaperon of endoplasmic reticulum and has immune modulating and antiapoptotic effects in hashimoto’s thyroiditis.
The study included 62 patients with autoimmune thyroiditis. Of these, 20 had euthyroid, 27 had subclinical hypothyroid, and 15 had hypothyroid hashimato’s thyroiditis. A control group including 37 healthy patients also participated in the study.
There was no statistically significant difference between subgroups of hashimoto’s thyroiditis patients and control group, and between subgroups of hashimoto’s thyroiditis patients, individually; when comparison was made in respect of Anti-BIP levels (p=0,889).
Although BIP activation has previously been shown, the Anti-BIP level was not different from the control group in subgroups of hashimoto’s thyroiditis patients in our study. This condition suggests that antibodies formed aganist BIP by apoptosis and/or T cell response are not associated with hashimoto’s thyroiditis or that it is at a level in serum that can not be measured
Aspectos ultrasonográficos da tireóide na doença de hashimoto.
No full textTrabalho de Conclusão de Curso - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Departamento de Clínica Médica, Curso de Medicina, Florianópolis, 200
Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo
No full textBACKGROUND: Immunotherapy based on Bi-specific T Cell Engagers (TCE) represents one of the most attractive strategy to treat cancers resistant to conventional therapies. TCE are antibody-like proteins that simultaneously bind with one arm to a Tumor Associated Antigen (TAA) on cancer cells and with the other one to CD3 complex on a T-cell to form a TCR-independent immune synapse and circumvent Human Leucocyte Antigen restriction. Among them, the tribodies, such as Tb535H, a bi-specific molecule, made up of a Fab and a scFv domain both targeting 5T4 and another scFv targeting CD3, have demonstrated anti-tumor efficacy in preclinical studies. METHODS: Here, we generated five novel tri-specific and multi-functional tribodies, called 53X tribodies, composed of a 5T4 binding Fab arm and a CD3 binding scFv, but differently from the parental Tb535H, they contain an additional scFv derived from an antibody specific for an immune checkpoint, such as PD-1, PD-L1 or LAG-3. RESULTS: Compared with the parental Tb535H bi-specific T cell engager targeting 5T4, the novel 53X tribodies retained similar binding properties of Tb535H tribody, but showed enhanced anti-tumor potency due to the incorporation of the checkpoint inhibitory moiety. In particular, one of them, called 53L10, a tri-specific T cell engager targeting 5T4, CD3 and PD-L1, showed the most promising anti-tumor efficacy in vitro and led to complete tumor regression in vivo. CONCLUSIONS: The novel tribodies have the potential to become strong and safe therapeutic drugs, allowing to reduce also the cost of production as one single molecule contains three different specificities including the anti-TAA, anti-CD3 and anti-IC binding arms
Letter, [Author unclear] to Paulina T. Merritt
No full textHandwritten letter to Paulina Merritt from an unknown author, October 1, 1876.
Hashimoto tiroiditi hastalarında işitsel fonksiyonların odyolojik değerlendirilmesi.
No full textAmaç:Hashimoto tiroiditi otoimmün bir hastalık olarak tanımlanmıştır. Tiroid
bezinin kronik bir iltihabıdır. Etyolojisi hala bilinmemekle beraber T-hücresi
infiltrasyonu ve tiroid bezine karşı oto-antikorların üretilmesi, hipotiroidizm,
ötiroidizm veya daha az sıklıkla hipertiroidizme yol açması ile karakterizedir.
Bizim çalışmamızın amacı da ilaç kullanan ve ilaç kullanmayan Hashimoto tiroiditi
hastalarının işitsel fonksiyonlarını değerlendirmektir.
Gereç ve Yöntem: Çalışmaya Hashimoto tiroiditi olup ilaç kullanan 30 hasta,
Hashimoto tiroiditi olup ilaç kullanmayan 19 hasta ve sağlıklı olan 29 gönüllü olmak
üzere toplam 77 kişi dahil edildi. Çalışmaya katılan kişilere öncelikle akustik
timponometri, saf ses odyometri, yüksek frekans odyometri, geçici uyarılmış
otoakustik emisyon ölçümleri yapıldı.
Bulgular: Hashimoto tiroiditi olup ilaç kullanan hastaların yaş ortalaması
48,33 ± 11,08, Hashimoto tiroiditi olup ilaç kullanmayan hastaların yaş ortalaması
41,78 ± 11,57 olup istatistiksel açıdan anlamlı bulunmadı(p=0,06). Hashimoto tiroiditi
olan hastaların yaş ortalaması 45,88 ± 11,60, kontrol grubu olan sağlıklı bireylerin yaş
ortalaması 34,10 ± 11,92 olup istatistiksel olarak anlamlı bulundu(p=0,00). İlaç
kullanan Hashimoto tiroiditi hastaları ile ilaç kullanmayan Hashimoto tiroiditi
hastaları arasında sağ kulak için 125 Hz, 250 Hz, 500 Hz ve 1000 Hz frekanslarında
istatistiksel olarak anlamlı bir fark bulunmuştur. İlaç kullanan Hashimoto tiroiditi
hastaları ile ilaç kullanmayan Hashimoto tiroiditi hastaları arasında sağ ve sol kulak
için 8 kHz – 18 kHz frekans aralığında istatistiksel olarak anlamlı bir fark
bulunmamıştır. Fakat Hashimoto tiroiditi ve sağlıklı grup sağ ve sol kulak için
karşılatırıldığında ise 8 kHz – 18 kHz frekans aralığında istatistiksel olarak anlamlı bir
fark bulunmuştur. İlaç kullanan Hashimoto tiroiditi ile ilaç kullanmayan Hashimoto
tiroiditi arasında 1 kHz, 1,43 kHz, 2 kHz, 2,83 kHz ve 4 kHz frekanslarda geçici uyarılmış otoakustik emisyon (TEOAE) açısından istatistiksel olarak anlamlı bir fark
bulunmamıştır.
Sonuç: Sonuç olarak elde ettiğimiz bulgular, Hashimoto tiroiditi hastalığında
işitsel disfonksiyon varlığını göstermektedir. Bu nedenle Hashimoto tiroiditi tanısı
konulduğunda hastaların odyolojik değerlendirmesi yapılmalı ve özellikle yüksek
frekanslarda belirgin düşüş gösterdiği için saf ses ortalamaya ek olarak yüksek frekans
odyometrinin klinikte ek seçenek olarak değil rutin işitme testleri arasına girmesi
sağlanmalıdır. Hastaların endokrin ve metabolizma kliniklerinde olası otolojik
tutulum hakkında bilgilendirilmesi sağlanmalıdır.
Objective: Hashimoto's thyroiditis is defined as an autoimmune disease. It is
a chronic inflammation of the thyroid gland. Although the etiology is still unknown,
T-cell infiltration and the generation of auto-antibodies against the thyroid gland are
characterized by hypothyroidism, euthyroidism, or less frequently hyperthyroidism.
The aim of our study was to evaluate the auditory functions of Hashimoto thyroiditis
patients who is taking medicine and is not taking medicine.
Materials And Methods: The study included 77 participants; 30 of them are
taking medicine, 19 of them are not taking medicine and 29 healthy people acoustic
timponometry, pure tone audiometry, high frequency audiometry, transient evoked
otoacoustic emission measurements were performed to the participants.
Results: The average age of Hashimoto's thyroiditis patients who are taking
medicine were 48.33 ± 11.08 years. The average age of patients with Hashimoto
thyroiditis were 41,78 ± 11,57 years and this difference was not statistically significant
(p= 0.06).The average age of patients with Hashimoto’s thyroiditis were 45,88±11,60
years. The average age of the healthy control group was 34,10 ± 11,92 years andthis
difference was statistically significant (p = 0.00). A statistically significant differences
were found at the frequencies of 125 Hz, 250 Hz, 500 Hz and 1000 Hz between the
Hashimoto’s thyroiditis patients who are taking the medicine and the Hashimoto
thyroiditis patients who are not using the medicine. There was no statistically
significant difference between Hashimoto’s thyroiditis patients who are using
medicine and Hashimoto’s thyroiditis patients who are not using medicine in the
frequency range of 8 kHz - 18 kHz for the right and left ear. However, when the
Hashimoto’s thyroiditis patient group and healthy group were compared for the right
and left ear, a statistically significant difference was found in the frequency range of 8
kHz to 18 kHz. There was no statistically significant difference between Hashimoto’s
thyroiditis patients who are taking medicine and Hashimoto’s thyroiditis patients who are not taking medicine in transient evoked autoacoustic emission (TEOAE) at 1 kHz,
1.43 kHz, 2 kHz, 2.83 kHz and 4 kHz.
Conclusion: Our results show that there is presence of auditory dysfunction in
Hashimoto thyroiditis patients. Therefore, the audiological evaluation of patients
should be done when Hashimoto thyroiditis is diagnosed. Especially, high-frequency
audiometry should be included in routine hearing tests, not as an additional option in
the clinical setting in addition to pure tone audiometry because of the significant
decrease in high frequencies. Patients should be informed about possible otologic
involvement in endocrine and metabolism clinics
- …
